Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Inks A Second Deal With PTC Therapeutics, Pays $30M Upfront

This article was originally published in The Pink Sheet Daily

Executive Summary

The Big Pharma teams up with a biotech and a patient advocacy foundation to develop treatments for a rare genetic disorder.

You may also be interested in...



PTC Adds To Management Team In Sign Of Progress Beyond Setbacks

The New Jersey-based biotech has not lost its optimism after a setback in Europe for its lead product and is showing growth in other areas.

Isis Moves SMA Drug Forward As Market Interest For The Rare Disease Expands

Spinal muscular atrophy is a rare disease that affects a small patient population of children. Isis is ready to move its compound into mid-stage testing after positive Phase I results, but the biotech isn’t the only company exploring the field.

Deals of the Week: Sanofi/Joslin; Merck/Ambrx; Genentech/AC Immune; GSK/Liquidia; Roche/Seaside

Walgreens’ deal to acquire Alliance Boots vastly expands its international presence but got a chilly reception on Wall Street.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS073102

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel